Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.96 |
| ▸ | PPARG | P37231 | 8/20 | 0.96 |
| ▸ | F7 | P08709 | 7/20 | 0.96 |
| ▸ | F3 | P13726 | 7/20 | 0.96 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.96 |
| ▸ | PPARD | Q03181 | 6/20 | 0.96 |
| ▸ | PPARA | Q07869 | 6/20 | 0.96 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.96 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.96 |
| ▸ | MAPT | P10636 | 4/20 | 0.96 |
| ▸ | OXER1 | Q8TDS5 | 4/20 | 0.96 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.96 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.96 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.96 |
| ▸ | LMNA | P02545 | 3/20 | 0.96 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.96 |
| ▸ | HPGD | P15428 | 3/20 | 0.96 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.96 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.96 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL606016 | 1.00 | ALDH1A1 (0.96) | ALDH1A1PPARGF7F3CYP19A1 | |
| SCHEMBL7750567 | 1.00 | ALDH1A1 (0.96) | ALDH1A1PPARGF7F3CYP19A1 | |
| SCHEMBL454567 | 1.00 | ALDH1A1 (0.96) | ALDH1A1PPARGF7F3CYP19A1 | |
| SCHEMBL4452324 | 1.00 | ALDH1A1 (0.96) | ALDH1A1PPARGF7F3CYP19A1 | |
| SCHEMBL10444556 | 1.00 | ALDH1A1 (0.96) | ALDH1A1PPARGF7F3CYP19A1 | |
| SCHEMBL7755119 | 1.00 | ALDH1A1 (0.96) | ALDH1A1PPARGF7F3CYP19A1 | |
| SCHEMBL14119798 | 1.00 | ALDH1A1 (0.96) | ALDH1A1PPARGF7F3CYP19A1 | |
| SCHEMBL7750573 | 1.00 | ALDH1A1 (0.96) | ALDH1A1PPARGF7F3CYP19A1 | |
| SCHEMBL15994740 | 1.00 | ALDH1A1 (0.96) | ALDH1A1PPARGF7F3CYP19A1 | |
| SCHEMBL29226 | 1.00 | ALDH1A1 (0.96) | ALDH1A1PPARGF7F3CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 317 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240050522-A1 | COMPOSITIONS AND METHODS FOR PREVENTING, ATTENUATING, AND TREATING MEDICAL CONDITIONS WITH sHDL NANOPARTICLES | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2024-02-15 | — | — | US | claimed |
| US-20230381202-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR RELATED DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-11-30 | — | — | US | claimed |
| EP-4259280-A1 | COMPOSITIONS AND METHODS FOR PREVENTING, ATTENUATING, AND TREATING MEDICAL CONDITIONS WITH SHDL NANOPARTICLES | The Regents Of The University Of Michigan (US) | 2023-10-18 | — | — | EP | claimed |
| EP-4232060-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR RELATED DISORDERS | The Regents Of The University Of Michigan (US) | 2023-08-30 | — | — | EP | claimed |
| EP-4021475-A1 | PEPTIDE INHIBITORS OF FOCAL ADHESION KINASE ACTIVITY AND USES THEREOF | Arizona Board of Regents on behalf of the University of Arizona (US) | 2022-07-06 | — | — | EP | claimed |
| WO-2022125878-A1 | COMPOSITIONS AND METHODS FOR PREVENTING, ATTENUATING, AND TREATING MEDICAL CONDITIONS WITH SHDL NANOPARTICLES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-06-16 | — | — | WO | claimed |
| WO-2022087058-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR RELATED DISORDERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-04-28 | — | — | WO | claimed |
| US-20220118059-A1 | COMPOSITION AND METHODS FOR MODULATION OF ELOVL2 | YOUHEALTH BIOTECH LTD (KY) | 2022-04-21 | — | — | US | claimed |
| WO-2021042064-A1 | PEPTIDE INHIBITORS OF FOCAL ADHESION KINASE ACTIVITY AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2021-03-04 | — | — | WO | claimed |
| US-10125078-B1 | NSAID derivatives of omega-3 polyunsaturated acids as gamma secretase modulators | JIVA PHARMA INC. (US) | 2018-11-13 | — | — | US | claimed |
| US-8859735-B2 | Gelatin alkyd peptides and uses thereof | EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) | 2014-10-14 | — | — | US | claimed |
| WO-2014160936-A2 | THIAZOLIDINEDIONES OF OMEGA-3 POLYUNSATURATED ACIDS AS NEW INSULIN SENSITIZERS FOR TREATING TYPE2 DIABETES | JIVA PHARMA, INC. (US) | 2014-10-02 | — | — | WO | claimed |
| WO-2014134053-A1 | ASCORBATE ESTERS OF OMEGA-3 FATTY ACIDS | JIVA PHARMA, INC. (US) | 2014-09-04 | — | — | WO | claimed |
| US-20140057053-A1 | GELATIN ALKYD PEPTIDES AND USES THEREOF | EMPIRE TECHNOLOGY DEVELOPMENT LLC | 2014-02-27 | — | — | US | claimed |
| US-8399516-B2 | Alpha-substituted omega-3 lipids that are activators or modulators of the peroxisome proliferators-activated receptor (PPAR) | PRONOVA BIOPHARMA NORGE AS (NO) | 2013-03-19 | — | — | US | claimed |
| JP-2010508259-A | — | — | 2010-03-18 | — | — | JP | claimed |
| US-20100035990-A1 | ALPHA-SUBSTITUTED OMEGA-3 LIPIDS THAT ARE ACTIVATORS OR MODULATORS OF THE PEROXISOME PROLIFERATORS-ACTIVATED RECEPTOR (PPAR) | PRONOVA BIOPHARMA NORGE AS (NO) | 2010-02-11 | — | — | US | claimed |
| EP-2094640-A1 | ALPHA-SUBSTITUTED OMEGA-3 LIPIDS THAT ARE ACTIVATORS OR MODULATORS OF THE PEROXISOME PROLIFERATORS-ACTIVATED RECEPTOR (PPAR). | Pronova BioPharma Norge AS (NO) | 2009-09-02 | — | — | EP | claimed |
| US-20090203778-A1 | FATTY ACID ANALOGUES, I.E. INCLUDING DHA DERIVATIVES FOR USES AS A MEDICAMENT | PRONOVA BIOPHARMA NORGE AS (NO) | 2009-08-13 | — | — | US | claimed |
| WO-2008053331-A1 | ALPHA-SUBSTITUTED OMEGA-3 LIPIDS THAT ARE ACTIVATORS OR MODULATORS OF THE PEROXISOME PROLIFERATORS-ACTIVATED RECEPTOR (PPAR). | PRONOVA BIOPHARMA NORGE A/S (SE) | 2008-05-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035990-A1 | ALPHA-SUBSTITUTED OMEGA-3 LIPIDS THAT ARE ACTIVATORS OR MODULATORS OF THE PEROXISOME PROLIFERATORS-ACTIVATED RECEPTOR (PPAR) | PPARG, PPARA, FFAR3 | ALDH1A1 1088/4885PPARG 1/4885F7 2774/4885 |
| US-10125078-B1 | NSAID derivatives of omega-3 polyunsaturated acids as gamma secretase modulators | PTGES3, PTGES, PTGER3 | ALDH1A1 2346/4885PPARG 108/4885F7 4816/4885 |
| US-20090203778-A1 | FATTY ACID ANALOGUES, I.E. INCLUDING DHA DERIVATIVES FOR USES AS A MEDICAMENT | ALOX12, ALOX15, ALOX5 | ALDH1A1 611/4885PPARG 35/4885F7 1488/4885 |
| US-20140057053-A1 | GELATIN ALKYD PEPTIDES AND USES THEREOF | NGLY1, TPD52L2, PLOD3 | ALDH1A1 1440/4885PPARG 3077/4885F7 2241/4885 |
| US-20230381202-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR RELATED DISORDERS | LOXL1, LOXL3, LOXL2 | ALDH1A1 2393/4885PPARG 2568/4885F7 2491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.